Enhancing Adherence in Breast Cancer Treatment with CDK4/6 Inhibitors Panel Discussion

Enhancing Adherence in Breast Cancer Treatment with CDK4/6 Inhibitors

This KOL commentary presented by Prof. Angelica Nogueira-Rodrigues and moderated by Prof. Lucia Del Mastro focused on the importance of treatment adherence in breast cancer patients using CDK 4/6 inhibitors, discussing factors influencing adherence, barriers, and strategies to improve it.

2:05 - Highlighting the importance of medication coverage in low and middle-income countries for patient adherence.

2:50 - Understanding the multifactorial causes of non-adherence, including financial problems, psychological impact, and physical impact.

8:06 - Emphasizing financial toxicity as a major barrier to access and adherence in low and middle-income countries.

8:16 - Identifying side effects such as fatigue, cognitive dysfunction, diarrhea, nausea, and myelotoxicity as factors influencing adherence to CDK 4/6 inhibitors.

10:02 - Implementing patient education programs to improve understanding of disease, treatment relevance, early recognition of side effects, and management strategies.

10:33 - Using simplified dosing regimens to enhance adherence and incorporating medication reminders for better adherence management.

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm